Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.

For oral semaglutide, improvement in BMI and body weight was numerically greater in group with BMI ≥ 35 kg/m 2 at baseline versus BMI < 35 kg/m 2 at baseline, although the difference did not reach statistical significance.

also in 111,027 other papers